EyePoint plunges after late-stage trial setback for lead drug against Eylea
MicroStockHub
EyePoint (EYPT) lost more than 80% in premarket trading on Monday after lead asset Duravyu failed in a late-stage trial that compared it against 2 mg of aflibercept, the best-selling eye disease therapy marketed by Regeneron (REGN) as Eylea.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.